• Maria Carolina Perissinotto, Carlos Arturo Levi DʼAncona, Adélia Lucio, Renata Martins Campos, and Anelyssa Abreu.
• Maria Carolina Perissinotto, PhD, Universidade Estadual de Campinas-Unicamp, Department of Urology, Campinas, São Paulo, Brazil. Carlos Arturo Levi D'Ancona, PhD, Universidade Estadual de Campinas-Unicamp, Department of Urology, Campinas, São Paulo, Brazil. Adélia Lúcio, PhD, Universidade Estadual de Campinas-Unicamp, Department of Urology, Campinas, São Paulo, Brazil. Renata Martins Campos, MSN, Universidade Estadual de Campinas-Unicamp, Department of Urology, Campinas, São Paulo, Brazil. Anelyssa Abreu, PhD, Universidade Estadual de Campinas-Unicamp, Department of Neurology, Campinas, São Paulo, Brazil.
• J Wound Ostomy Continence Nurs. 2015 Jan 1; 42 (1): 94-9.

PurposeA randomized controlled trial study was performed to evaluate the efficacy of transcutaneous tibial nerve stimulation (TTNS) and sham TTNS, in patients with Parkinson disease (PD) with lower urinary tract symptoms (LUTS).DesignRandomized controlled trial.Subjects And SettingsThirteen patients with a diagnosis of PD and bothersome LUTS were randomly allocated to one of the following groups: Group I: TTNS group (n = 8) and group II: Sham group (n = 5). Both groups attended twice a week during 5 weeks; each session lasted 30 minutes.MethodsEight patients received TTNS treatment and 5 subjects allocated to group II were managed with sham surface electrodes that delivered no electrical stimulation. Assessments were performed before and after the treatment; they included a 3-day bladder diary, Overactive Bladder Questionnaire (OAB-V8), and the International Consultation on Incontinence Quality of Life Questionnaire Short Form (ICIQ-SF), and urodynamic evaluation.ResultsFollowing 5 weeks of treatment, patients allocated to TTNS demonstrated statistically significant reductions in the number of urgency episodes (P = .004) and reductions in nocturia episodes (P < .01). Participants allocated to active treatment also showed better results after treatment in the OAB-V8 and ICIQ-SF scores (P < .01, respectively). Urodynamic testing revealed that patients in the active treatment group showed improvements in intravesical volume at strong desire to void (P < .05) and volume at urgency (P < .01) when compared to subjects in the sham treatment group.ConclusionThese findings suggest that TTNS is effective in the treatment of LUTS in patients with PD, reducing urgency and nocturia episodes and improving urodynamic parameters as well as symptom scores measured by the OAB-V8 and health-related quality-of-life scores measured by the ICIQ-SF.

23 keywords...

hide…